<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469884</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001</org_study_id>
    <secondary_id>CRAD001ABR20T</secondary_id>
    <nct_id>NCT01469884</nct_id>
  </id_info>
  <brief_title>Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients</brief_title>
  <acronym>CONCERVIC</acronym>
  <official_title>A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Irmandade Santa Casa de Misericórdia de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Irmandade Santa Casa de Misericórdia de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the viral load of hepatitis c virus in patients converted to certican versus patients
      who are maintained on calcineurin inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The infection by hepatitis C virus (HCV) is the leading cause of chronic liver disease in
      renal transplant recipients.

      The prevalence of pretransplantation anti-HCV is 11% to 49%. The impact of HCV infection on
      patient survival after renal transplant remains controversial. Some studies also showed that
      patients undergoing renal transplantation anti-HCV positive are associated with a reduction
      in graft and patient survival.Chronic infection of HCV is associated with an increased number
      of infections.

      In HCV positive renal transplant patients have been shown that there is an increase from four
      to seven times in HCV viremia after transplantation compared to pretransplant.

      To prevent viral replication, immunosuppression must be adapted, involving a balance between
      control of viral replication and rejection.

      Biochemically, the NS5A protein has been linked to increased replication of the hepatitis C
      virus through p70S6K phosphopeptides. Sirolimus as inhibitor of pathway mTOR/p70S6K reduced
      in vivo phosphorylation of NS5A phosphopeptides and thus viral replication. Moreover, the
      mTOR protein has been proven in vitron to have a protective role against apoptosis in HCV
      infected cells (WAGNER et al., 2010).

      Wagner et al. (2010) showed a beneficial effect of sirolimus on viral recurrence monitored by
      transaminases and viral load as well as by histological data. They also reported the improved
      survival after liver transplantation due to hepatitis C for patients receiving sirolimus
      rather than calcineurin inhibitor-based regimens.

      In the literature there have already been reported good virological control of HCV among
      liver transplant recipients after conversion to SRL and the reduction of hepatitis C virus
      recurrence (GALLEGO et al., 2009; BENEDETTOET al., 2010).

      Everolimus has shown a potent inhibitor of mTOR and has been widely used as an
      immunosuppressive agent in kidney transplant, but no reported effects on HCV progression was
      found in the literature.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in viral load of hepatitis C virus at 12 months after randomization.</measure>
    <time_frame>Baseline,Months 3, 6, 9 and 12 after randomization</time_frame>
    <description>HCV viremia will be measured by polymerase chain reaction (PCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute allograft rejection</measure>
    <time_frame>Weeks 1, 2, 3, months 1, 3, 6, 9 and 12 after randomization</time_frame>
    <description>All patients will perform at least 07 protocol visits and should be performed renal biopsy during screening phase and during the follow up if present renal dysfunction or proteinuria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of significant infections</measure>
    <time_frame>Weeks1, 2, 3 and months 1, 3, 6,9 and 12 after randomization</time_frame>
    <description>During the study visits the patient will be evaluated by a doctor and it will perform blood tests to assess their clinical conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of proteinuria</measure>
    <time_frame>Months 1, 3, 6, 9 and 12 after randomization</time_frame>
    <description>Spot urine sample for protein and creatinine will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of malignance</measure>
    <time_frame>Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization</time_frame>
    <description>Medical evaluation will be performed during the protocol visits and if necessary biopsy and exams of imaging to confirm any suspected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of dyslipidemia</measure>
    <time_frame>Months 1, 3, 6, 9 and 12 after randomization</time_frame>
    <description>Lipid levels: total cholesterol, HLD, LDL and triglycerides will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of liver impairment</measure>
    <time_frame>Months 1, 3, 6, 9, and 12 after randomization</time_frame>
    <description>Blood chemistry: TGO/AST, TGP/ALT , GGT and alkaline phosphatase will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of post-transplant diabetes</measure>
    <time_frame>Months 1, 3, 6, 9 and 12</time_frame>
    <description>Blood chemistry: Glucose will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of hypertension</measure>
    <time_frame>Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization</time_frame>
    <description>Vital signs will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft loss survival</measure>
    <time_frame>Weeks 1, 2 , 3 and months 1, 3 ,6, 9 and 12 after randomization</time_frame>
    <description>Graft survival will be evaluated by our team doctor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>Weeks 1, 2, 3 and months 1, 3, 6, 9 and 12 after randomization</time_frame>
    <description>Subject survival will be evaluated by our team doctor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Renal Allograft</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Certican®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm1(conversion):Certican®+mycophenolate+prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus or Cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.</description>
    <arm_group_label>Certican®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Trough level should be between 100 and 200ng/ml.</description>
    <arm_group_label>Tacrolimus or Cyclosporine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Trough level should be between 5 and 10ng/ml.</description>
    <arm_group_label>Tacrolimus or Cyclosporine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age ≥ 18 years at the time of screening;

          -  Subjects between the first and tenth year after renal transplantation;

          -  Subjects with positive serology for hepatitis C;

          -  Subjects receiving calcineurin inhibitor (tacrolimus or cyclosporine) plus
             mycophenolate sodium or mofetil plus prednisone since the first month post-transplant;

          -  Subjects with no acute rejection episode in the last 3 month;

          -  Women of childbearing potential (CBP) with a negative pregnancy test at screening
             (urine or serum;

          -  Women of CBP and men with sexual partners of CBP must agree to use a medically
             acceptable method of contraception throughout the study. The investigator will
             determine which contraceptive method more effective and appropriate for each study
             subject. Acceptable methods of contraception include oral contraceptives, barrier
             methods (eg, diaphragm or condom with spermicide) and intrauterine devices.

        Exclusion criteria:

          -  Subjects who, in the opinion of the investigator, are not able to complete the study;

          -  Recipients of multiple organ transplant (i.e., prior or concurrent transplantation of
             a non-renal allograft;

          -  Subjects with a calculated GFR &lt; 30ml/min (abbreviated MDRD formula;

          -  Subjects with Urinary protein/creatinine &gt; 0.5;

          -  Renal biopsy with score ≥ Banff grade II interstitial fibrosis and tubular atrophy
             (Banff 2007;

          -  Subjects with a history of biopsy-proven acute rejection within 12 weeks of
             enrollment;

          -  Known or suspected hypersensitivity to inhibitor of mTOR;

          -  Subjects with a history of primary or recurrent FSGS, membranous glomerulonephritis
             (MGN) or membranoproliferative glomerulonephritis (MPGN);

          -  Evidence of any active systemic or localized major infection;

          -  Use of any investigational drug or treatment up to 4 weeks before enrollment;

          -  Immunosuppressive therapies other than those described by this protocol;

          -  Planned systemic treatment with voriconazole, cisapride or ketoconazole that will not
             be discontinued before randomization;

          -  Prior treatment with aminoglycosides, amphotericin B, cisplatin or other drugs
             associated with renal dysfunction that is not discontinued before screening;

          -  Subjects with a screening total white blood cell count (WBC) ≤ 2000/mm3, hemoglobin ≤
             10g/dL and platelet count ≤ 100000/mm3;

          -  TGO/AST, TGP/ALT and bilirubins with values three times higher than reference values;

          -  Fasting triglycerides ≥ 400 mg/dL, fasting total cholesterol ≥ 350 mg/dL or
             LDL-cholesterol ≥ 160mg/dL despite the use of optimal lipid-lowering therapy;

          -  History of malignancy within 3 years before enrollment other than adequately treated
             basal cell or squamous cell carcinoma of the skin;

          -  Subjects who are known to be human immunodeficiency virus (HIV) positive or hepatitis
             B positive;

          -  Chronic hepatic failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valter Garcia, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ELIZETE KEITEL, Physician</last_name>
    <role>Study Chair</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARIANA F RODRIGUES, PHARMACIST</last_name>
    <role>Study Director</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DIEGO GNATTA, PHARMACIST</last_name>
    <role>Study Director</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LARISSA S PACHECO, PHARMACIST</last_name>
    <role>Study Director</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BRUNA D CARDOSO, PHARMACIST</last_name>
    <role>Study Director</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RONIVAN L DAL PRA, PHARMACIST</last_name>
    <role>Study Director</role>
    <affiliation>IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irmandade Da Santa Casa de Misericórdia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90020090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Di Benedetto F, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, Guerrini GP, Spaggiari M, Guaraldi G, Gerunda G. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation. 2010 Mar 27;89(6):733-8. doi: 10.1097/TP.0b013e3181c7dcc0.</citation>
    <PMID>20048692</PMID>
  </reference>
  <reference>
    <citation>Boletis JN, Iniotaki-Theodoraki A, Psichogiou M, Stamatiadis DN, Viglis JV, Kostakis A, Stavropoulos-Giokas C. Immune status in renal transplant recipients with hepatitis C virus infection. Transplant Proc. 2002 Dec;34(8):3205-8.</citation>
    <PMID>12493421</PMID>
  </reference>
  <reference>
    <citation>Gallego R, Henriquez F, Oliva E, Camacho R, Hernández R, Hortal L, Sablón N, Quintana B, Santana R, Gonzalez F, Palop L, Vega N. Switching to sirolimus in renal transplant recipients with hepatitis C virus: a safe option. Transplant Proc. 2009 Jul-Aug;41(6):2334-6. doi: 10.1016/j.transproceed.2009.06.064.</citation>
    <PMID>19715912</PMID>
  </reference>
  <reference>
    <citation>Ingsathit A, Thakkinstian A, Kantachuvesiri S, Sumethkul V. Different impacts of hepatitis B virus and hepatitis C virus on the outcome of kidney transplantation. Transplant Proc. 2007 Jun;39(5):1424-8.</citation>
    <PMID>17580153</PMID>
  </reference>
  <reference>
    <citation>Mas, V.; Alvarellos, T.; Chiurchiu, C.; Camps, D.; Massari, P.; Boccardo, G. Hepatitis C Virus Infection After Renal Transplantation: Viral Load and Outcome. Transplantation Proceedings, 33, 1791-1793, 2001. Ridruejo, E.; Cusumano, A.; Diaz, C.; Dávalos Michel. M.; Jost, L.; Jost, L.; Soler Pujol, G.; Mandó, O. G.; Vilches, A. Hepatitis C Virus Infection and Outcome of Renal Transplantation. Transplantation Proceedings , 39, 3127-3130, 2007.</citation>
  </reference>
  <reference>
    <citation>Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation. 2001 Jul 27;72(2):241-4.</citation>
    <PMID>11477346</PMID>
  </reference>
  <reference>
    <citation>Wagner D, Kniepeiss D, Schaffellner S, Jakoby E, Mueller H, Fahrleitner-Pammer A, Stiegler P, Tscheliessnigg KH, Iberer F. Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates. Int Immunopharmacol. 2010 Aug;10(8):990-3. doi: 10.1016/j.intimp.2010.05.006. Epub 2010 May 17.</citation>
    <PMID>20483386</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Irmandade Santa Casa de Misericórdia de Porto Alegre</investigator_affiliation>
    <investigator_full_name>Valter Duro Garcia</investigator_full_name>
    <investigator_title>PHYSICIAN NEPHROLOGY</investigator_title>
  </responsible_party>
  <keyword>Renal allograft recipients</keyword>
  <keyword>Hepatitis C virus (HCV)</keyword>
  <keyword>Certican</keyword>
  <keyword>Calcineurin inhibitor(tacrolimus or cyclosporin)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

